510(k) Report

510(k) · Cleared

Cleared

Elecsys Psa Assay

K964351510(k) TraditionalCleared Jul 25, 1997266-day reviewClass II21 CFR 866.6010

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Boehringer Mannheim Corp. · LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers

Cleared on Jul 25, 1997 after a 266-day review. The FDA summary names its predicate without a number. 2 later devices descend from it.

Decided
Jul 25, 1997
Review
266 days
Class
Class II
Product code
LTJ
Recalls
None
Predicates
0

2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 1998: 2 descendants cleared1995200020052010201520202025
  1. This deviceK964351 Elecsys Psa AssayBoehringer Mannheim Corp. · 1997
  2. Descendant · cites it directly · 0 of its ownK982949 Elecsys Psa, Model 2010Boehringer Mannheim Corp. · 1998
  3. Descendant · cites it directly · 0 of its ownK974189 Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp. · 1998

Most influential descendants

Showing 2 of 2 · See all
  • K982949Elecsys Psa, Model 2010Boehringer Mannheim Corp. · 1998 · cites it directly0descendants
  • K974189Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp. · 1998 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K964351Elecsys Psa AssayBoehringer Mannheim Corp.1997—
+1K982949Elecsys Psa, Model 2010Boehringer Mannheim Corp.1998—
+1K974189Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp.1998—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
199820
FIG. 1 — Lineage of K964351, 1997–1998Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LTJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LTJ device

  1. #1 K251630 Atellica IM Total PSA II (tPSAII)score 10.6 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—Tosoh Aia-Pack PA
Named without a submission number
—

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K982949Elecsys Psa, Model 2010Boehringer Mannheim Corp.19980
K974189Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp.19980

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K982949 (Boehringer Mannheim Corp., 1998) has gone furthest, with 0 descendants of its own.

How does its category compare?

All LTJ devices

LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LTJ

3in 2025

2013: 12016: 22017: 102018: 72019: 22020: 12021: 22023: 22024: 32025: 32026 (partial year): 3
2007high 10 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LTJ

Too few LTJ 510(k)s in any year since 2007 to give a median.

Recalls per year · LTJ

1in 2025

2008: 32010: 22013: 12025: 1
2007high 3 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LTJ

14in 2025

2007: 172008: 572009: 582010: 342011: 1092012: 1012013: 692014: 192015: 142016: 82017: 132018: 82019: 112020: 42021: 82022: 112023: 172024: 82025: 14
2007high 109 (2011) · low 4 (2020)2025

MAUDE reports naming product code LTJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—017
20080—357
20090—058
20100—234
20110—0109
20120—0101
20131—169
20140—019
20150—014
20162—08
201710—013
20187—08
20192—011
20201—04
20212—08
20220—011
20232—017
20243—08
20253—114
20263—0—

What is it indicated for?

Immunoassay for the in vitro quantitative determination of Prostate-Specific Antigen in human serum and plasma. The Elecsys PSA assay is further indicated for serial measurement of PSA to aid in the management of prostate cancer,

The electrochemiluminescence immuncassay “ECLIA” is intended for use on the Boshringer Mannheim Elecsys 2010 immunoassay analyzers.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K964351: Elecsys Psa Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K964351

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026